Research Analysts’ Recent Ratings Updates for Zenas BioPharma (ZBIO)

Several brokerages have updated their recommendations and price targets on shares of Zenas BioPharma (NASDAQ: ZBIO) in the last few weeks:

• 6/3/2026 – Zenas BioPharma had its “buy” rating reaffirmed by Citigroup Inc..
• 6/3/2026 – Zenas BioPharma had its “buy” rating reaffirmed by HC Wainwright.
• 5/16/2026 – Zenas BioPharma was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/15/2026 – Zenas BioPharma was upgraded by Zacks Research from “strong sell” to “hold”.
• 5/15/2026 – Zenas BioPharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.
• 5/14/2026 – Zenas BioPharma had its price target raised by Morgan Stanley from $21.00 to $22.00. They now have an “equal weight” rating on the stock.
• 5/14/2026 – Zenas BioPharma had its “buy” rating reaffirmed by Citigroup Inc..

Insider Activity at Zenas BioPharma

In related news, CEO Leon O. Moulder, Jr. acquired 60,000 shares of Zenas BioPharma stock in a transaction that occurred on Monday, May 18th. The stock was acquired at an average price of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the acquisition, the chief executive officer directly owned 96,928 shares of the company’s stock, valued at $1,636,144.64. This trade represents a 162.48% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Hongbo Lu acquired 3,768 shares of Zenas BioPharma stock in a transaction that occurred on Tuesday, March 31st. The stock was bought at an average cost of $18.63 per share, with a total value of $70,197.84. Following the acquisition, the director directly owned 426,736 shares of the company’s stock, valued at approximately $7,950,091.68. This trade represents a 0.89% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 273,768 shares of company stock worth $5,150,198 in the last three months. 22.00% of the stock is owned by company insiders.

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.